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OBJECTIVE: To describe the degree of difficulty that HIV-infected patients have with therapy treatment. 
INTRODUCTION: Patients’ perceptions about their treatment are a determinant factor for improved adherence and a better qual-
ity of life. 
METHODS: Two cross-sectional analyses were conducted in public AIDS referral centers in Brazil among patients initiating treat-
ment. Patients interviewed at baseline, after one month, and after seven months following the beginning of treatment were asked 
to classify and justify the degree of difficulty with treatment. Logistic regression was used for analysis. 
RESULTS: Among 406 patients initiating treatment, 350 (86.2%) and 209 (51.5%) returned for their first and third visits, respec-
tively. Treatment perceptions ranged from medium to very difficult for 51.4% and 37.3% on the first and third visits, respectively. 
The main difficulties reported were adverse reactions to the medication and scheduling. A separate logistic regression indicated 
that the HIV-seropositive status disclosure, symptoms of anxiety, absence of psychotherapy, higher CD4+ cell count (> 200/mm3)
and high (> 4) adverse reaction count reported were independently associated with the degree of difficulty in the first visit, while 
CDC clinical category A, pill burden (> 7 pills), use of other medications, high (> 4) adverse reaction count reported and low un-
derstanding of medical orientation showed independent association for the third visit. 
CONCLUSIONS: A significant level of difficulty was observed with treatment. Our analyses suggest the need for early assess-
ment of difficulties with treatment, highlighting the importance of modifiable factors that may contribute to better adherence to 
the treatment protocol.
KEYWORDS: AIDS. Treatment. Patient Perception. Adherence. Modifiable Factors. 
INTRODUCTION
Antiretroviral therapy (ART) has brought important 
benefits to HIV-infected patients, such as increased sur-
vival, better quality of life, significant reduction in the 
incidence of opportunistic infections and lower costs 
related to ambulatory care and hospitalization.1,2,3 The 
Brazilian National STD/AIDS Program of the Ministry of 
Health has guaranteed universal and free access to ART 
since 1996.4 Patients diagnosed in that year had a median 
survival three times longer than those diagnosed in 1995, 
clearly indicating the benefits of ART.5 The clinical goals 
of HIV treatment and care, including maximizing survival 
and improving quality of life, are optimally accomplished 
only through a high-level of adherence to ART and, con-
sequently, a durable suppression of the HIV viral load.6
Non-adherence has become a common cause of therapy 
failure, with failure rates varying from 7.0% to 43.0% in 
different health care settings worldwide.7-14 Factors poten-
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tially associated with non-adherence include characteristics 
related to the antiretroviral regimen (e.g., complexity of 
therapy, pill burden, food requirements, adverse reactions), 
a patient’s perception of the treatment, the interference of 
ART in a patient’s daily life, symptoms of AIDS and level 
of education, among others.8-15 However, there are few pub-
lished epidemiologic studies that investigate the difficulties 
reported by patients initiating antiretroviral therapy, and to 
our knowledge, none in Brazil. Patients may feel emotion-
ally unprepared for treatment due to a lack of understand-
ing and/or belief in ART, leading to increased difficulties 
with everyday treatment management.16-17 Identifying and 
understanding the difficulties that arise in the beginning 
of treatment may help prevent further episodes of non-
adherence and potentially increase long-term adherence 
with sustainable clinical benefits and improvement in pa-
tient quality of life.16,17 The present study aimed to describe 
the degree of difficulty with ART reported by HIV-infected 
patients in public AIDS reference centers using two cross-
sectional analyses issued subsequent to the beginning of 
treatment (after one and seven months). In addition, we 
explored potential factors associated with such difficulties, 
including sociodemographic, psychosocial, clinical and 
health care-related variables.
MATERIALS AND METHODS
Subjects
This analysis is part of a prospective concurrent study 
conducted at two public health referral centers in a large 
metropolitan city in Brazil. The objective of the main proj-
ect was to estimate the incidence of non-adherence to ART 
among patients initiating treatment and the factors associated 
with it. Briefly, eligibility criteria were serologic-confirmed 
HIV infection; no prior history of antiretroviral use; age over 
18 years old (or 16 years old for pregnant women); having 
had one’s first antiretroviral regimen dispensed in one of 
the centers and voluntarily participation consent. Patients 
were interviewed after first receiving medication (baseline 
interview), and subsequently in the first, fourth and seventh 
month of follow-up. The project was approved by the Ethi-
cal Committee Board of both participating centers and the 
Federal University of Minas Gerais (ETIC 106/99).
Exposure and event measurements
Data were collected using a pre-tested semi-structured 
questionnaire consisting of closed and short open-ended 
questions. Face-to-face interviews were conducted by trained 
research personnel in private rooms. Sociodemographic (e.g., 
gender, age, schooling, income), behavioral (e.g., disclosure 
of HIV-seropositive status, condom use and alcohol and 
injection drug use), health services and clinical character-
istics (e.g., difficulty of access to services, embarrassment, 
understanding of medical orientation) were obtained dur-
ing baseline interviews, while data on ARV use (e.g., dif-
ficulties with the treatment, prescribed regimens, change in 
regimen, pill burden, adverse reactions and adherence) were 
obtained from each follow-up interview. Additionally, the 
CDC clinical classification18 and CD4+ T-lymphocyte count 
were obtained from medical charts during the study period. 
Symptoms of anxiety and depression were assessed using the 
Hospital Anxiety and Depression Scale during the baseline 
interview.19 Disclosure of one’s HIV-seropositive status was 
self-reported and defined as having communicated an HIV 
positive result to a close acquaintance such as a relative, 
friend or sexual partner. 
For the current analysis, the outcome measurement (i.e., 
the difficulty of antiretroviral therapy use) was assessed in 
a cross-sectional approach at the first (first month) and third 
(seventh month) visits. We used only these visits as points 
of comparison because the time between the first and second 
visits was brief. Patients were asked to classify the degree of 
difficulty of their treatment at each visit as very high, high, 
medium, low, or very low and to justify their choice. The 
reported reasons were classified as problems associated with 
adverse reactions, scheduling, pill burden, emotional status, 
adaptation, social interactions, health care service, organo-
leptic properties of the drugs or dietary interference. 
Data analysis
Descriptive analysis was conducted for the reported 
difficulties while crude associations were assessed by chi-
square test. The degree of difficulty was categorized as a 
dichotomous variable, comparing all values falling between 
medium and very high difficulty to those in the range of low 
to very low difficulty, due to power considerations. The mag-
nitude of the associations between putative risk factors and 
the degree of difficulty with treatment was estimated by the 
odds ratio (OR) with a 95% confidence interval (95% CI). 
The independent effect of potential exposure variables was 
assessed by multivariate analysis using logistic regression for 
each visit. All variables with p-values equal to or less than 
0.20 obtained in the univariate analysis were used to begin 
multivariate modeling. A backward deletion strategy was ap-
plied, and those variables with p-values equal to or less than 
0.05 remained in each of the final models. Goodness of fit 
was evaluated using the Hosmer-Lemeshow test,20 while the 
SAS System® and EGRET for Windows®, were used for data 
analysis, and Paradox® was used for data storage. 
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RESULTS
Of the 406 participants enrolled in the study, 362 (89.2%) 
patients returned for the first and 218 (53.7%) for the third 
visit after initiating ART. Twelve and nine patients did not 
classify the degree of difficulty of their treatment in the first 
or third visits, leaving 350 (86.2%) and 209 (51.5%) patients 
for analysis, respectively. No difference was observed when 
comparing the two visits for most variables, although there 
were fewer participants in the third visit. Descriptive data 
indicated that, for both visits, most participants were male, 
younger than 35 years old, and had less then 8 years of 
schooling, a low individual monthly income and no health 
insurance (Table 1). While more than half of the sexually-
active participants reported always using condoms in the last 
month, fewer patients reported alcohol or injection drug use 
for both periods. Similarly, most patients had disclosed their 
HIV-seropositive status to relatives or friends while fewer 
participants declared embarrassment during clinic visits, 
reported some difficulty of access to the health service or 
were receiving psychotherapy. Clinical markers indicated 
high proportions of patients with lower CD4+ T-lymphocyte 
count (< 200 cells/mm3) or with CDC clinical classification 
B or C. Protease inhibitors were commonly prescribed, while 
a reasonable proportion of patients reported more than four 
adverse reactions or had a low understanding of their pre-
scription’s medical orientation. 
Overall, 51.4% (n=180) patients found their treatment to 
be of medium to high difficulty in the first visit while this 
rating frequency dropped to 37.3% (n=78) in the third visit 
(Table 2). Adverse reactions were the main reason reported 
(33.3%), followed by complex scheduling (23.9%), among 
those reporting medium to high degree of difficulty in the 
first visit. Less frequent reasons were those associated with 
emotional status (9.4%), social interaction (7.2%), pill bur-
den (6.7%), health care service (6.1%) and the organoleptic 
properties of the drugs (5.6%). On the other hand, adverse 
reactions only accounted for 19.2% and scheduling became 
the foremost difficulty by the third visit (37.2%). Among 
those with less difficulty with the treatment overall, the main 
reason reported was scheduling, while there was an increase 
in treatment adaptation over time (23.5% and 32.1%, for the 
first and third visits, respectively) (Table 2).
Univariate analysis indicated similar proportions of 
patients with increased difficulty with treatment across age, 
schooling, income, condom, alcohol or injection drug use, 
for both visits. Although more patients reported a change 
in regimen in the first visit, this was not associated with 
greater difficulty with treatment (data not shown). On the 
other hand, at the first visit, an increased degree of difficulty 
(p-value < 0.05) was found for those who disclosed their 
Table 1 - Descriptive characteristics of participants in the first 
(n=350) and third (n=209) follow-up visits, ATAR Project, 
2001-2003
Characteristics 1st visit
n (%)
3rd visit
n (%)
Sociodemographic:
Gender (male) 195 (55.7) 124 (59.3)
Age (< 35 y.o.) 208 (59.4) 110 (52.6)
Schooling (< 8 years) 184 (52.6)  99 (47.6)
Individual monthly income 
(< USD 80)*
212 (61.6) 123 (60.0)
No health insurance 276 (78.9) 152 (72.7)
Behavioral:
HIV-seropositive status disclosure** 297 (86.3) 181 (87.9)
Always used condom in the last 
month**
 95 (55.6)  52 (57.8)
Alcohol use in the last month** 127 (36.9)  74 (35.9)
Lifetime injection drug use**  17 ( 4.9)  13 ( 6.3)
Clinical and health service related:
Difficulty of access to health 
service**
 33 ( 9.6)  22 (10.7)
Embarrassment during clinic visits**  48 (14.0)  28 (13.6)
Anxiety (Moderate/Severe)** 123 (36.0)  78 (38.0)
Low understanding of medical 
orientation**
108 (30.9)  65 (31.1)
ART regimen (with protease 
inhibitor)***
161 (46.0)  94 (45.0)
Change in ART***  39 (11.1)  13 ( 6.2)
Pill burden (> 7 pills a day)*** 180 (51.4) 101 (48.3)
Use of other medication*** 187 (53.4)  94 (45.0)
? 4 adverse reactions*** 161 (46.0)  77 (36.8)
Time between 1st office visit and 
1st ART prescription (> 90 days)**
112 (32.0)  63 (30.1)
Clinical category B or C 
(CDC 1993)**
166 (49.8) 107 (53.0)
CD4+ T-lymphocytes count 
(< 200 cells/mm3)**
132 (52.4)  96 (59.3)
* US dollar;** Baseline data;*** Follow-up data
HIV-seropositive status, reported embarrassment during 
clinic visits, had a higher CD4+ T-lymphocyte count (> 
200 cells/mm3), presented moderate to severe symptoms of 
anxiety, had ? 4 adverse reactions and had experienced a 
longer time period between the first HIV medical visit and 
the first antiretroviral prescription (> 3 months). Borderline 
significance was observed for difficulty of access to services, 
168
CLINICS 2008;63(2):165-72Difficulties reported by HIV-infected patients using antiretroviral therapy in Brazil
Guimarães MDC et al.
psychotherapy attendance and being clinically asymptomatic 
(Table 3). Fewer factors were statistically associated (p-
value < 0.05) with difficulty with treatment in the third visit, 
including higher CD4+ T-lymphocyte counts (> 200 cells/
mm3), ARV antiretroviral regimen with protease inhibitor, 
daily pill burden (? 7 pills), use of other medication, ? 4 
adverse reactions and low understanding of medical orien-
tation. It should be noted that women had more difficulties 
with treatment in the third visit, although this result is only 
of borderline significance (p=0.068).
Adjusted OR with 95% CI are shown in Table 4. Because 
women showed a statistically-independent borderline asso-
ciation during the third visit (p=0.081), we decided to retain 
this variable in the final model of each visit for comparison 
purposes. HIV-seropositive status disclosure, ? 4 adverse 
reactions reported, presence of symptoms of anxiety and ab-
sence of psychotherapy were independently associated with 
the degree of difficulty in the first visit while CDC clinical 
category A, pill burden (> 7 pills), use of other medication, ?
4 adverse reactions reported and low understanding of one’s 
medical orientation were associated with difficulties during 
the third visit, in addition to gender.
DISCUSSION
By using several simple questions, we were able to as-
sess patient perception of difficulties related to initial ART. 
We chose to compare visits at two separate, cross-sectional 
Table 2 - Number and distribution of the degree of difficulties and reasons reported by patients in the first and third visits. 
ATAR Project, 2001-2003
Degree of Difficulty (Reasons reported) First visit n=350 Third visit n=209
n (%) n (%)
Medium to Very High 180 (51.4) * 78 (37.3) *
Adverse Reactions (Nausea, Diarrhea, Nightmares, Feeling bad with medication)  60 (33.3) ** 15 (19.2) **
Scheduling (I forget to take the drugs, The regimen is complex)  43 (23.9) ** 29 (37.2) **
Emotional status (I’m feeling too depressed, I feel hopeless)  17 ( 9.4) **  9 (11.5) **
Social Interactions (It’s difficult to take the drugs at work, I can’t go out in the weekends)  13 ( 7.2) **  6 ( 7.7) **
Pill burden (Too many pills, So many pills make me anxious)  12 ( 6.7) ** 8 (10.3) **
Health care service (I don’t understand the treatment, I live far from the clinic)  11 ( 6.1) ** 3 ( 3.8) **
Organoleptic properties of drugs (Bad taste, The pills are too big, they are difficult to 
swallow)
 10 ( 5.6) ** 3 ( 3.8) **
Adaptation (It’s hard to get used to it)  9 ( 5.0) ** 3 ( 3.8) **
Dietary interference (Sometimes I forget fasting, I have to take with meals)  3 ( 1.7) ** 2 ( 2.6) ** 
Reason not reported  2 ( 1.1) ** -
Low to Very Low 170 (48.6) * 131 (62.7) *
Scheduling (Easy schedule, Only two times a day)  51 (30.0) ** 45 (34.4) **
Adaptation (The regimen is easy to adapt)  40 (23.5) ** 42 (32.1) **
Health care service (Medicines are free, I was well oriented) 23 (13.5) **  11 ( 8.4) **
Adverse Reactions (I don’t feel anything, No adverse reactions)  19 (11.2) ** 19 (14.5) **
Emotional status (I’m feeling better, More hopeful)  16 ( 9.4) **  5 ( 3.8) **
Social Interactions (My family helps me, Don’t need to hide)  8 ( 4.7) **  -
Pill burden (Few pills, Only two medicines)  4 ( 2.4) ** 4 ( 3.1) **
Organoleptic properties of drugs (It’s easy to swallow)  -  1 ( 0.8) **
Dietary interference (It doesn’t need fasting)  2 ( 1.2) **  3 ( 2.3) **
Reason not reported  7 ( 4.1) **  1 ( 0.8) **
* Percent from total in each visit; ** Percent from each category (medium to very high and low to very low) in each visit
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Table 3 - Univariate analysis of the degree of difficulty according to selected characteristics (p-value < .020) in the first and 
third visits, ATAR Project, 2001-2003
Characteristics First Visit (n=350) Third Visit (n=209)
Total n (%)* OR (95% CI) p-value Total n n (%)* OR (95% CI) p-value
Gender
Male
Female
195
155
101 (51.8) 
79 (51.0)
1.00
0.97 (0.63 – 1.48) 0.878
124
85
40 (32.3) 
38 (44.7)
1.00
1.70 (0.96 – 3.00) 0.068
HIV-seropositive status disclosure**
No
Yes
47
297
18 (38.3) 
160 (53.9)
1.00
1.88 (1.00 – 3.54) 0.047
25
181
7 (28.0) 
71 (39.2)
1.00
1.66 (0.66 – 4.18) 0.278
Difficulty of access to health service**
No
Yes
309
33
155 (50.2) 
22 (66.7)
1.00
1.99 (0.93 – 4.24) 0.071
183
22
72 (39.3) 
6 (27.3)
1.00
0.58 (0.22 – 1.55) 0.271
Embarrassment during clinic visits**
No
Yes
295
48
146 (49.5) 
32 (66.7)
1.00
2.04 (1.07 – 3.88) 0.027
178
28
65 (36.5) 
13 (46.4)
1.00
1.51 (0.68 – 3.36) 0.315
Attendance to psychotherapy**
Yes 
No
35
308
13 (37.1) 
165 (53.6)
1.00
1.95 (0.95 – 4.02) 0.065
22
184
6 (27.3) 
72 (39.1)
1.00
1.71 (0.64 – 4.59) 0.279
Clinical category (CDC 1993)**
B or C 
A
166
167
79 (47.6) 
95 (56.9)
1.00
1.45 (0.94 – 2.24) 0.089
107
95
36 (33.6) 
41 (43.2)
1.00
1.50 (0.85 – 2.65) 0.165
CD4+ T-lymphocytes count**
? 200/mm3
> 200/mm3
Unknown
132
120 98
60 (45.5) 
73 (60.8) 
47 (48.0)
1.00
1.78 (1.14 – 2.80) 
0.82 (0.52 – 1.32)
0.011
0.206
96
66
47
34 (35.4) 
30 (45.5) 
14 (29.8)
1.00
1.65 (0.91 – 2.99) 
0.64 (0.32 – 1.31)
0.010
0.206
Degree of anxiety**
None / Mild 
Moderate / Severe
209
123
101 (46.1) 
75 (61.0)
1.00
1.83 (1.17 – 2.86) 0.008
127
78
50 (39.4) 
28 (35.9)
1.00
0.86 (0.48 – 1.55) 0.619
Anti-retroviral therapy***
Without protease inhibitor 
With protease inhibitor
189
161
93 (49.2) 
87 (54.0)
1.00
1.21 (0.80 – 1.85) 0.367
115
94
33 (28.7) 
45 (47.9)
1.00
2.28 (1.29 – 4.04) 0.004
Pill burden***
? 7 pills 
> 7 pills
170
180
82 (42.8) 
98 (54.4)
1.00
1.28 (0.84 – 1.95) 0.245
108
101
30 (27.8) 
48 (47.5)
1.00
2.36 (1.33 – 4.18) 0.003
Use of other medication***
No
Yes
162
187
83 (51.2) 
96 (51.3)
1.00
1.00 (0.66 – 1.53) 0.985
115
94
36 (31.3) 
42 (44.7)
1.00
1.77 (1.01 – 3.12) 0.047
Report of adverse reactions to ART***
< 4 
? 4
189
161
81 (42.9) 
99 (61.5)
1.00
2.13 (1.39 – 3.27) 0.001
132
77
42 (31.8) 
36 (46.8)
1.00
1.88 (1.01 – 3.36)
0.031
Time between 1st office visit and 1st prescription of ART
? 3 months 
> 3 months
238
112
111 (46.6) 
69 (61.6)
1.00
1.84 (1.16 – 2.90) 0.009
146
63
52 (35.6) 
26 (41.3)
1.00
1.27 (0.69 – 2.33) 0.438
Degree of understanding of medical orientation**
High
Low
242
108
124 (51.2) 
56 (51.9)
1.00
1.03 (0.65 – 1.61) 0.916
144
65
46 (31.9) 
32 (49.2)
1.00
2.07 (1.14 – 3.76) 0.017
*Number and proportion of medium to high degree of difficulty in each category; **Baseline data; ***Follow-up data
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time points due to power considerations, despite the known 
limitation of cross-sectional designs with regard to causal 
inferences. However, we should emphasize that no differ-
ence was observed with regard to non-participation rates 
and most variables were similarly distributed between the 
two periods. In addition, patients at these centers represented 
approximately 90% of all reported AIDS cases during the 
study period for the region. 
Notably, a high proportion of patients indicated a high 
degree of difficulty in the beginning of treatment (51.4%). 
Health care-related variables seem to have played a more 
important role in the first visit, while treatment and clini-
cal characteristics were more prominent in the third visit. 
Although most sociodemographic variables were not statisti-
cally associated with our outcome of interest, women tended 
to report more difficulties, but only for the third visit, and 
this with borderline significance. This is corroborated by 
other data indicating that women may have higher rates of 
non-adherence21 or a poorer quality of life.22 Because of the 
need to cope with their partners’ and/or children’s treatment, 
women often fail to adhere to their own treatment, which 
may partially explain the finding from the third visit.23
Factors related to health care providers are crucial for pa-
tients initiating ART therapy, including compliance to regular 
clinic visits, counseling, availability of support services and 
a multidisciplinary approach. A complete understanding of 
the complexity of the regimen, side effects and scheduling, 
among other concerns, may help patients deal with their 
medication with less difficulty. In addition, earlier access to 
care and counseling before actual ART may help prepare pa-
Table 4 - Final multivariate analysis of the degree of difficulty 
in the first and third visits, ATAR Project, 2001-2003
Characteristics OR ( 95% CI) p-value
First Visit (n=350)*
Gender (female) 0.91 (0.57 – 1.45) 0.691
HIV-seropositive status disclosure 2.00 (1.01 – 3.97) 0.046
No psychotherapy 2.20 (0.99 – 4.91) 0.053
CD4+ T-lymphocytes count(> 200/mm3)* 2.07 (1.21 – 3.53) 0.007
? 4 adverse reactions 1.82 (1.14 – 2.90) 0.012
Moderate or severe anxiety 1.69 (1.02 – 2.80) 0.040
Third Visit (n=209)**
Gender (female) 1.79 (0.93 – 3.42) 0.081
Clinical Category “A” (CDC 1993) 2.17 (1.12 – 4.20) 0.021
Pill burden (> 7 pills) 3.06 (1.60 – 5.86) <0.001
Use of other medication 2.29 (1.19 – 4.38) 0.013
> 4 adverse reactions 1.81 (0.94 – 3.46) 0.074
Low understanding of medical orientation 2.27 (1.16 – 4.46) 0.017
* Hosmer-Lemeshow test: ?2=6.965 (degrees of freedom=8); p-value=0,540; 
** Hosmer-Lemeshow test: ?2=6.655 (degrees of freedom=7); 
p-value=0,466
tients for long-term treatment effects and reinforce the need 
for high adherence. As shown, patients with a longer time 
between their initial medical visit and their antiretroviral pre-
scription and those who reported embarrassment were more 
likely to have increased difficulties with the treatment in the 
first visit, although these results did not remain in the final 
statistical model. Factors such as irregular medical visits, 
discontinuation of their clinical follow-up24 and poor health 
professional-patient relationships25,26 may indirectly explain 
such findings. In addition, particularly related are the lack of 
psychotherapy and the presence of moderate-to-severe symp-
toms of anxiety, which were also associated with increased 
difficulty in the first visit. This may clearly indicate the lack 
of adequate psychiatric counseling by trained professionals 
in these services before treatment started, as shown in other 
studies27.
Clinical- and treatment-related factors were found to be 
barriers for good adherence. Although adverse reactions re-
mained statistically significant in both visits, they were more 
common in the first visit and indicated a stronger early effect 
of treatment. They were also more commonly cited as the 
main reason for difficulty with treatment in the first relative 
to the third visit, at rates of 33.3% and 19.2%, respectively. 
This is consistent with the literature, which indicates that 
adverse effects are related to a decrease in the quality of 
life and low adherence among HIV-treated patients.21,28-30 
However, ART is a dynamic phenomenon, which changes 
over time, as patients tend to adapt their daily routine to 
regimen scheduling and more readily learn how to identify 
and deal with side effects.31 As shown, better scheduling and 
easier adaptation were the most common reasons reported 
by those patients with low to very low difficulty in the third 
visit (34.4% and 32.1%, respectively). However, pill burden, 
the inclusion of regimens with protease inhibitor and the ad-
ditional use of other medications over time are factors which 
also tend to create more difficulties. Additionally, it should 
be noted that poor understanding of medical orientation 
remained a predictor of difficulties only for the third visit. 
This may indicate that, even if adequately counseled when 
beginning treatment, long-lasting and sustained good levels 
of information may not be feasible if routine counseling 
and reminders by health professionals are not continuously 
received by patients. Finally, the association of a higher 
CD4+ cell count and the asymptomatic patient designation 
(CDC classification A) with increased difficulties may reflect 
a lower perception of these patients with regard to the need 
for treatment, and thus a lower threshold for dealing with the 
daily burden of ART regimens. 
Findings from these analyses suggest the need for early 
assessment of factors associated with increased difficulties 
and therefore the need to identify patients who are at a great-
171
CLINICS 2008;63(2):165-72 Difficulties reported by HIV-infected patients using antiretroviral therapy in Brazil
Guimarães MDC et al.
er risk of lower adherence before starting treatment. Health 
care professionals and AIDS referral services must develop 
focused interventions to address modifiable factors such 
as compliance with medical visits, counseling, improved 
physician-patient relationships and better ARV orientation 
to achieve immediate and sustainable adherence.
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